drugset / Trial / NCT07096557

The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus

NCT07096557

Phase 2 Completed 60 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of coenzyme Q10 supplementation in pediatric patients with SLE. The main questions it aims to answer are: * What is the impact of coenzyme Q10 supplementation on mitochondrial dysfunction? * Does it have a beneficial effect on disease activity through assessment of the systemic lupus erythematosus disease activity index (SLEDAI) score? Researchers will compare the group of patients that take coenzyme Q10 to a group that doesn't to see if coenzyme Q10 supplementation works to decrease mitochondrial dysfunction and disease activity. Participants will: Take coenzyme Q10 plus the standard treatment of SLE or the standard treatment only every day for 3 months. Visit the clinic once every 4 weeks for checkups and tests.

Timeline

Start
2024-01-01
Primary completion
2024-11-10
Completion
2025-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme Q10 Other / unclassified 100 mg